NCT02314169 2026-04-22
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5,755 trialsNCT03138720 2026-04-22
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Completed
NCT03210714 2026-04-22
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03981146 2026-04-22
ANICCA
University of Birmingham
Phase 2 Completed
NCT04858334 2026-04-22
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04891289 2026-04-22
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05655949 2026-04-22
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06423326 2026-04-22
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
NCT07353684 2026-04-22
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
Beijing Friendship Hospital
Phase 2 Recruiting
NCT07450859 2026-04-22
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited
Phase 2 Recruiting
NCT07521852 2026-04-22
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
NCT07543783 2026-04-22
Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07543848 2026-04-22
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer
Chongqing University Cancer Hospital
Phase 2 Not yet recruiting
NCT07544784 2026-04-22
APSOC
Fudan University
Phase 2 Recruiting
NCT02782949 2026-04-21
Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03213678 2026-04-21
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT05009069 2026-04-21
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05103904 2026-04-21
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Terminated
NCT05308446 2026-04-21
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05480384 2026-04-21
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Phase 2 Active not recruiting
NCT05836584 2026-04-21
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06860490 2026-04-21
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
Phase 2 Recruiting
NCT07407647 2026-04-21
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07434843 2026-04-21
PEMIGIST
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07542002 2026-04-21
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Ningbo Medical Center Lihuili Hospital
Phase 2 Recruiting
NCT07542262 2026-04-21
NIVO402025
Blokhin's Russian Cancer Research Center
Phase 2 Enrolling by invitation
NCT02437851 2026-04-20
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
AIDS Malignancy Consortium
Phase 2 Completed
NCT03301805 2026-04-20
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
Rgene Corporation
Phase 2 Not yet recruiting
NCT03485209 2026-04-20
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT04074135 2026-04-20
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05632328 2026-04-20
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT06792695 2026-04-20
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT07205731 2026-04-20
SAFE ESO
University Hospital, Clermont-Ferrand
Phase 2 Recruiting
NCT07539311 2026-04-20
RAINFOL-09
Genmab
Phase 2 Not yet recruiting
NCT02713269 2026-04-17
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05197322 2026-04-17
NEOPRISM-CRC
University College, London
Phase 2 Recruiting
NCT05513742 2026-04-17
COMPANION-003
Compass Therapeutics
Phase 2 Completed
NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT06050252 2026-04-17
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06760702 2026-04-17
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Terminated
NCT06855225 2026-04-17
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT07406633 2026-04-17
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
NCT07523763 2026-04-17
NIVO1002024
Blokhin's Russian Cancer Research Center
Phase 2 Active not recruiting
NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07537348 2026-04-17
LUCENT-GC-03
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT07537361 2026-04-17
LUCENT-GC-02
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting